News and Announcements
Imugene Receives Acceptance for Leading Clinical Drug
- Published February 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company has been developing a leading clinical drug called HER-Vaxx for treatment of gastric cancer patients.
KEY TAKEAWAYS:
- Today the company received a Notice of Acceptance form the Australian Patent Office for Patent Application.
Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer. Aa recently published in the journal BMC Cancer, and announced February 13, 2017, the enhanced formulation of HER-Vaxx incorporates an existing, clinically and commercially validates vaccine carrier protein.
“The strengthening of our patent portfolio is an important milestone and underpins our commercialisation strategy,” said Ms. Leslie Chong, Chief Executive Officer of Imugene.
Also adding “This new patent protects HER-Vaxx until 2036 which is significantly longer than the vast majority of completing clinical stage products and technologies. The additional patent life adds an additional six years to the time HER-Vaxx could remain generating peak sales, adding to the total amount of potential sales achievable by HER-Vaxx and hence significantly increasing the value of HER-Vaxx.”
To read the full ASX Announcement, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
